Triterpenoid Therapeutics Inc.
Boston, MA
- UEI
- JA25GYTMYJP3
- CAGE
- 87EX3
- Primary NAICS
- 813920 Professional Organizations
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 68 Bellevue St, Boston, MA 02132, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Topic 430: a new small molecule senotherapeutic for the chemoprevention of therapy-related cognitive aging | National Cancer Institute (NIH) | $400,000 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Atux Iskay Group LLC | Plainsboro Township, NJ | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Acepre, LLC | Columbia, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Nuvox Pharma, L.L.C. | Tucson, AZ | 541713 Research and Development in Nanotechnology |
| Mirimus, Inc. | NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Triterpenoid Therapeutics Inc. is a corporate entity registered in SAM.gov as a self-certified small disadvantaged business and for-profit organization. It appears to be a biotech or pharmaceutical company focused on developing new drugs and therapies, particularly targeting cancer and other diseases.
Triterpenoid Therapeutics Inc. has received federal contract awards from the National Institutes of Health (NIH) National Cancer Institute. In September 2022, it was awarded a $400,000 firm fixed price Small Business Innovation Research (SBIR) Phase I contract to conduct research on "A New Small Molecule Senotherapeutic for the Chemoprevention of Therapy-Related Cognitive Aging" under Topic 430. This 17-month contract was set aside for total small business participation and is being performed in Lebanon, New Hampshire. It aims to develop medical technologies and innovative solutions aligned with NIH and CDC public health goals.
Triterpenoid Therapeutics Inc. has also received federal grant awards from the NIH National Cancer Institute. In September 2020, it was awarded a $399,908 project grant for the "Development of the New Synthetic Triterpenoid CDDO-2P-IM (TTX01) for Glioblastoma" which lasted until August 2022. Additionally, in September 2020, the company received a $530,281.41 project grant for the "Development of the New Synthetic Triterpenoid CDDO-2P-IM for Chemoprevention of the ARDS of COVID-19" which ended in February 2022. These grants funded the company's research and development efforts related to new drug candidates targeting cancer and COVID-19 respiratory distress.
Quick answers
Is Triterpenoid Therapeutics Inc. registered in SAM.gov?
Yes. Triterpenoid Therapeutics Inc.'s SAM.gov registration is active through December 4, 2026.
What is Triterpenoid Therapeutics Inc.'s most recent federal award?
Triterpenoid Therapeutics Inc.'s most recent federal contract award is Topic 430: a new small molecule senotherapeutic for the chemoprevention of therapy-related cognitive aging (75N91022C00030), from National Cancer Institute (NIH), on September 16, 2022.
On GovTribe
See Triterpenoid Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors